ZAROXOLYN TABLET

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

METOLAZONE

Fáanlegur frá:

SANOFI-AVENTIS CANADA INC

ATC númer:

C03BA08

INN (Alþjóðlegt nafn):

METOLAZONE

Skammtar:

2.5MG

Lyfjaform:

TABLET

Samsetning:

METOLAZONE 2.5MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

100

Gerð lyfseðils:

Prescription

Lækningarsvæði:

THIAZIDE-LIKE DIURETICS

Vörulýsing:

Active ingredient group (AIG) number: 0109680001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2000-12-01

Vara einkenni

_ZAROXOLYN_
_®_
_ (metolazone) _
_ _
_Page 1 of 23_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
ZAROXOLYN®
Metolazone Tablets
2.5 mg Tablets
USP
Diuretic/Antihypertensive
sanofi-aventis Canada Inc.
2905 Place Louis-R.-Renaud
Laval, Quebec
H7V 0A3
Date of Initial Authorization:
December 31, 1974
Date of Revision:
December 30, 2022
Submission Control Number: 265721
_ _
_ZAROXOLYN_
_®_
_ (metolazone) _
_Page 2 of 23_
RECENT MAJOR LABEL CHANGES
7
WARNINGS AND PRECAUTIONS
12/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
4
4.1
Dosing Considerations
.......................................................................................
4
4.2
Recommended Dose and Dosage
Adjustment..................................................... 4
4.5
Administration...................................................................................................
5
4.6
Missed Dose
......................................................................................................
5
5
OVERDOSA